NCT04079738View on ClinicalTrials.gov

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 20, 2019

Primary Completion Date

September 22, 2021

Study Completion Date

February 23, 2022

Conditions
AMLAML, Adult
Interventions
DRUG

TAK-659

TAK-659

DRUG

Ixazomib

Ixazomib

Trial Locations (1)

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

H Scott Boswell

OTHER